These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31059726)

  • 41. #Checkmate: could checkpoint inhibitors be the game changer in the fight against metastatic urothelial carcinoma?
    Dhariwal R; Pindoria N; Dasgupta P; Khan MS
    BJU Int; 2019 Feb; 123(2):203-207. PubMed ID: 29974606
    [No Abstract]   [Full Text] [Related]  

  • 42. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
    Ellis PM; Vella ET; Ung YC
    Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pembrolizumab in the treatment of advanced urothelial cancer.
    Lundgren KT; Farina MS; Bellmunt J
    Future Oncol; 2017 Dec; 13(30):2745-2758. PubMed ID: 29219016
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [An elderly case of squamous cell lung cancer treated continuously with pembrolizumab without any decline in the life function].
    Sazuka M; Murano Y; Takada K; Nonaka K; Yamada H; Yamamoto H
    Nihon Ronen Igakkai Zasshi; 2018; 55(4):679-685. PubMed ID: 30542036
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The benefits of immunotherapy combinations.
    Schmidt C
    Nature; 2017 Dec; 552(7685):S67-S69. PubMed ID: 29293245
    [No Abstract]   [Full Text] [Related]  

  • 46. Therapeutics: Spoilt for choice.
    Eisenstein M
    Nature; 2017 Nov; 551(7679):S36-S38. PubMed ID: 29117155
    [No Abstract]   [Full Text] [Related]  

  • 47. Focal immune-related pancreatitis occurring after treatment with programmed cell death 1 inhibitors: a distinct form of autoimmune pancreatitis?
    Capurso G; Archibugi L; Tessieri L; Petrone MC; Laghi A; Arcidiacono PG
    Eur J Cancer; 2018 May; 95():123-126. PubMed ID: 29530539
    [No Abstract]   [Full Text] [Related]  

  • 48. Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer.
    Hill A; Gong J; Wilczynski S; Mirza R; Erhunmwunsee L; Salgia R
    J Oncol Pract; 2018 Sep; 14(9):569-571. PubMed ID: 30044685
    [No Abstract]   [Full Text] [Related]  

  • 49. Durvalumab in urothelial cancers.
    Lavaud P; Hamilou Z; Loriot Y; Massard C
    Expert Rev Anticancer Ther; 2018 Apr; 18(4):311-318. PubMed ID: 29486607
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Major response to pembrolizumab in two patients with locally advanced cutaneous squamous cell carcinoma.
    Degache E; Crochet J; Simon N; Tardieu M; Trabelsi S; Moncourier M; Templier I; Foroni L; Lemoigne A; Pinel N; Gil H; Bouillet L; Leccia MT; Charles J
    J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e257-e258. PubMed ID: 28557105
    [No Abstract]   [Full Text] [Related]  

  • 51. The current status of checkpoint inhibitors in metastatic bladder cancer.
    Fahmy O; Khairul-Asri MG; Stenzl A; Gakis G
    Clin Exp Metastasis; 2016 Oct; 33(7):629-35. PubMed ID: 27380916
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dynamics of Immune Checkpoints, Immune System, and BCG in the Treatment of Superficial Bladder Cancer.
    Saad FT; Hincal E; Kaymakamzade B
    Comput Math Methods Med; 2017; 2017():3573082. PubMed ID: 29312460
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Keytruda Crosses First-Line Finish Line First.
    Reinke T
    Manag Care; 2017 May; 26(5):24. PubMed ID: 28661847
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Emerging role of checkpoint inhibition in localized bladder cancer.
    Singh P; Black P
    Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immune checkpoint therapy in proteinuric kidney disease.
    Takenaka T; Kawai Y; Amano T
    Eur J Cancer; 2018 May; 95():120-122. PubMed ID: 29530540
    [No Abstract]   [Full Text] [Related]  

  • 56. Are targeted agents the key to unlock the code for immune checkpoint inhibitors in soft-tissue sarcomas?
    Assi T
    Future Oncol; 2019 Oct; 15(28):3185-3187. PubMed ID: 31578878
    [No Abstract]   [Full Text] [Related]  

  • 57. Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy.
    Venniyoor A
    Saudi J Kidney Dis Transpl; 2019; 30(4):998-999. PubMed ID: 31464264
    [No Abstract]   [Full Text] [Related]  

  • 58. A patient with acquired factor X deficiency and metastatic transitional cell carcinoma of the bladder: is there a link between metastasis and factor deficiency in solid tumors?
    Cammaert T; Decaestecker K; Sundahl N; Rottey S; Devreese KMJ
    Ann Hematol; 2018 Mar; 97(3):545-546. PubMed ID: 29130135
    [No Abstract]   [Full Text] [Related]  

  • 59. Myasthenia Gravis After Nivolumab Therapy for Squamous Cell Carcinoma of the Bladder.
    Chang E; Sabichi AL; Sada YH
    J Immunother; 2017 Apr; 40(3):114-116. PubMed ID: 28234667
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metastatic cutaneous apocrine adenocarcinoma responsive to the programmed cell death protein 1 inhibitor pembrolizumab.
    Rogatsch M; Schmid J; Lax S; Uranitsch M; Schmid-Zalaudek K; Giuffrida R; Zalaudek I
    Eur J Cancer; 2018 Feb; 90():146-148. PubMed ID: 29237537
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.